Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Next Year to See “Dawn of New Age” of Interferon-Free Hepatitis C Treatment: Dr Kumada
November 28, 2014
- Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
- J-CLEAR’s Kuwajima Criticizes Plan to Legally Regulate Clinical Research
November 12, 2014
- ICH-GCP Compliance Obligatory for Clinical Studies Conducted by Chiba University
October 28, 2014
- Chiba University Issues Warning to Prof. Involved in VART Study
October 28, 2014
- JSH to Draft Guidelines on Clinical Research with Company Funding
October 21, 2014
- St. Marianna Hospital Elbows Drug Makers to Reveal Detailing Costs Embedded in Drug Prices
October 10, 2014
- Japanese Society of Hypertension Announces Resignation of President
October 1, 2014
- Rivaroxaban as Safe and Effective as Standard Therapy in Japanese DVT Patients: J-EINSTEIN DVT Study
September 30, 2014
- Safety and Efficacy of Secukinumab Confirmed for Psoriasis in Japanese Patients
September 24, 2014
- Dr Yui Poses Questions on Dabigatran Analysis Model on BMJ
September 9, 2014
- Prof. Komuro to Issue Objection to Chiba University in Wake of Second Retraction Request Related to VART Study
September 9, 2014
- Kyoto University, Astellas Aim to Develop Immunological Disease Cures, 11 Target Molecules Now under Screening
August 21, 2014
- Chiba Univ. Once Again Advises Authors to Withdraw Papers from VART Study
August 19, 2014
- Japanese Circulation Society Issues Warning Letter to Dr Matsubara and Co-Authors in Connection with Diovan Scandal
August 15, 2014
- JSH to Adopt Tougher COI Rule after Panel Said Novartis’s Involvement in SIGN Trial Should Have Been Disclosed at Conference
August 5, 2014
- Japanese Respiratory Society Chairman Calls for Addition of Spirometry to Medical Checkups to Detect COPD
August 4, 2014
- Digestive System Cancer Expert Calls for Early Approval of RAS Gene Mutation Kit
July 31, 2014
- Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator
July 16, 2014
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…